Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 2/20 | 0.34 |
| ▸ | DDO | Q99489 | 2/20 | 0.34 |
| ▸ | AHR | P35869 | 2/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 4/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1741436 | 0.82 | TNF (0.38) | TNFRIPK1GPR84DAODDO | |
| SCHEMBL8649018 | 0.82 | DAO (0.37) | DAODDOAHRTYRUSP2 | |
| SCHEMBL24625869 | 0.81 | DAO (0.36) | TNFRIPK1GPR84DAODDO | |
| SCHEMBL18876104 | 0.81 | TNF (0.46) | TNFRIPK1NR3C1GPR84AHR | |
| SCHEMBL21752742 | 0.78 | CSNK2A1 (0.38) | TNFRIPK1NR3C1GPR84AHR | |
| SCHEMBL12818798 | 0.75 | CYP2D6 (0.37) | TNFRIPK1GPR84AHRGRM5 | |
| SCHEMBL12818797 | 0.75 | TNF (0.37) | TNFRIPK1NR3C1GPR84AHR | |
| SCHEMBL12803764 | 0.74 | MPO (0.33) | TNFRIPK1NR3C1GPR84AHR | |
| SCHEMBL12804155 | 0.73 | EIF4A3 (0.33) | TNFRIPK1NR3C1GPR84AHR | |
| SCHEMBL8055277 | 0.72 | TNF (0.39) | TNFRIPK1NR3C1AHRTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855456-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-20150250767-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250767-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | TNF 1733/4885RIPK1 3457/4885NR3C1 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.